Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

2 août 2012 mis à jour par: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center

Phase II Trial of OSI-774 (Tarceva), a Human Epidermal Growth Factor (HER) (erbB, Also Known as Epidermal Growth Factor Receptor, EGFR) Tyrosine Kinase Inhibitor, in Treatment-Naïve Operable Breast Cancer

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with breast cancer that can be removed by surgery.

Aperçu de l'étude

Description détaillée

OBJECTIVES:

Primary

  • To determine the in situ antitumor effect of neoadjuvant erlotinib hydrochloride as measured by a reduction in Ki67 and/or an increase in terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL)-positive tumor cells in patients with treatment-naive, operable breast cancer.

Secondary

  • To identify a molecular profile, based on measurements of Estrogen Receptor (ER), Epidermal Growth Factor Receptor (EGFR), and a Human Epithelial Growth Factor Receptor-2(HER2), and protein expression profiles in patients with treatment-naïve, operable breast cancer that is responsive to erlotinib hydrochloride.
  • To correlate tumor concentrations of erlotinib hydrochloride with serum levels immediately before surgery.

OUTLINE: This is a multi-center study.

Patients receive oral erlotinib hydrochloride once daily for 5-14 days. Patients then undergo surgical resection within 24 hours after the last dose of erlotinib hydrochloride.

Tumor tissue samples are collected at baseline and during surgery for correlative laboratory studies. Tissue samples are stained for ER, HER2, and EGFR levels, proliferation (Ki67), and apoptosis (TUNEL) by immunohistochemistry. Levels of erlotinib hydrochloride in tissue samples are measured by matrix-assisted laser desorption/ionization mass spectrometry. Blood samples are collected on the day of surgery. Levels of erlotinib hydrochloride in blood samples are measured by liquid chromatography/mass spectrometry.

Patients are followed within 6 weeks after surgery.

Type d'étude

Interventionnel

Inscription (Réel)

50

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Alabama
      • Birmingham, Alabama, États-Unis, 35249
        • University of Alabama, Birmingham
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Dana-Farber Cancer Institute
    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27514
        • Lineberger Comprehensive Cancer Center
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37232
        • Vanderbilt-Ingram Cancer Center
      • Nashville, Tennessee, États-Unis, 37208
        • Meharry Medical College

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Clinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma

    • Diagnosis may be made by fine needle aspiration cytology or core biopsy

      • A repeat core biopsy is not required for patients who have a paraffin embedded diagnostic core biopsy specimen available for immunohistochemical staining

Exclusion Criteria:

  • Patients with locally advanced disease who are planning to undergo preoperative neoadjuvant therapy are not eligible*

    • Locally advanced disease includes any of the following:

      • Primary tumor ≥ 5 cm (T3)
      • Tumor of any size with direct extension to the chest wall or skin (T4a-c)
      • Inflammatory breast cancer (T4d)
      • Fixed axillary lymph node metastases (N2)
      • Metastasis to ipsilateral internal mammary node (N3) NOTE: *Patients with primary tumors ≥ 5 cm (T3) or tumors involving the chest wall or skin who are not candidates for preoperative chemotherapy or who decline preoperative chemotherapy are eligible
  • Measurable residual tumor at the primary site

    • Measurable disease is defined as any mass that can be reproducibly measured by physical examination
  • Planning to undergo surgical treatment with either segmental resection or total mastectomy
  • Patients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer
  • No locally recurrent breast cancer
  • No evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases)
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Menopausal status not specified
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • ANC ≥ 1,000/mm^3
  • Creatinine ≤ 1.5 times upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 times ULN
  • Serum glutamic oxaloacetic transminase (SGOT) and serum glutamic pyruvic transminase (SGPT) ≤ 1.5 times ULN
  • Must be at least 18 years old
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No serious medical illness that, in the judgement of the treating physician, places the patient at high risk of operative mortality

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior chemotherapy for this primary breast cancer
  • At least 7 days since prior tamoxifen or raloxifene as a preventive agent

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Tarceva
Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
Autres noms:
  • OSI-774
  • erlotonib
Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
Used to determine blood plasma levels of Erlotinib on the day of surgery
Autres noms:
  • (LC/MS)
Used to determine blood plasma levels of Erlotinib on the day of surgery
Autres noms:
  • (LC/MS)
After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
Autres noms:
  • MALDI MS
Surgical treatment will occur within 24-hours following completion of therapy.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants Experiencing in Situ Anti-tumor Effect of Tarceva
Délai: 5-14 days
In situ anti-tumor effect of Tarceva as measured by a minimum 75% reduction in Ki67 compared to pre-treatment tumor cells in patients with operable breast cancer.
5-14 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Molecular Profile of Participants Who Are Responsive to Tarceva
Délai: at 5-14 days
Determined by estrogen receptor status (ER) and human epidermal growth factor receptor 2 (HER2) status, which are measured by staining of 200-500 tumor cells and noting the number stained. Positive = > 10% of cell show staining, negative = < 10% of cells show staining
at 5-14 days
Average Post-treatment Plasma Level of Erlotinib Hydrochloride
Délai: After last dose of Tarceva, at 5-14 days, and before surgery
Post-treatment plasma level in µmol/L of erlotinib hydrochloride
After last dose of Tarceva, at 5-14 days, and before surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Carlos L. Arteaga, MD, Vanderbilt-Ingram Cancer Center

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 août 2002

Achèvement primaire (Réel)

1 octobre 2007

Achèvement de l'étude (Réel)

1 octobre 2007

Dates d'inscription aux études

Première soumission

11 mars 2008

Première soumission répondant aux critères de contrôle qualité

11 mars 2008

Première publication (Estimation)

12 mars 2008

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

5 septembre 2012

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 août 2012

Dernière vérification

1 juillet 2012

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • VICC BRE 0222
  • P50CA098131 (Subvention/contrat des NIH des États-Unis)
  • VU-VICC-BRE-0222
  • VU-VICC-020448
  • R01CA080195 (Subvention/contrat des NIH des États-Unis)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner